Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis.

Publication Title

Biomedicines

Authors

Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow
Elisabeth B Lucassen, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USAFollow
Meghan C Romba, Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR 97225, USAFollow
Stefanie N Linch, Providence Health and Services, Regional Research Department, Portland, OR 97213, USAFollow

Document Type

Article

Publication Date

3-11-2019

Keywords

CD25; DRESS; autoimmunity; daclizumab; drug reaction with eosinophilia systemic symptoms; innate immune system; interleukin-2; relapsing multiple sclerosis

Abstract

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences